Developments in pancreatic cancer surgery
- PMID: 37943494
- DOI: 10.1007/s13304-023-01692-4
Developments in pancreatic cancer surgery
Abstract
Pancreatic cancer surgery, with one of the worst prognoses in oncology, is a challenge to the surgical community. Centralization of pancreatic surgery has led to the foundation of high-volume centers, thereby greatly facilitating the successful performance of more radical approaches. This review spotlights on recent advances in surgical approaches to pancreatic cancer and the risks and benefits of vascular reconstruction to improve resectability. Surgery being the only modality to achieve cure, multivisceral and vascular resections are being incorporated to improve dismal operability rates of < 10%. Great leaps have been made in neoadjuvant and adjuvant treatment, as targeted and specific chemotherapeutic agents are being continually added. The concept of borderline and locally advanced pancreatic tumors and the use of neoadjuvant chemorad has extended the indications of oncological resection in such tumors. Venous resections are being routinely performed so as to facilitate en bloc removal of tumors, while arterial resections, owing to the increased morbidity and mortality, are offered to highly selective cases. New techniques like the triangle operation and periarterial divestment have opened new viable surgical options. Although laparoscopic approach is time consuming, it offers reduced operative blood loss and a shortened hospital stay at specialized centers. Robotic surgery may produce better results in patients needing vascular resection and reconstruction, but the expenses involved and limited availability are major deterrents. Advanced techniques of surgical resection and vessel reconstruction provide a repository for curative-intent surgery in borderline resectable and locally advanced pancreatic cancer.
Keywords: Artery-first approaches; Centralization; High-volume center; Pancreatic cancer; Vascular resections in pancreatic surgery.
© 2023. Italian Society of Surgery (SIC).
References
-
- Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30. https://doi.org/10.3322/caac.21387 - DOI - PubMed
-
- Liu Q, Liao Q, Zhao Y (2017) Chemotherapy and tumor microenvironment of pancreatic cancer. Cancer Cell Int 17:68. https://doi.org/10.1186/s12935-017-0437-3 - DOI - PubMed - PMC
-
- Mann O, Strate T, Schneider C et al (2006) Surgery for advanced and metastatic pancreatic cancer—current state and perspectives. Anticancer Res 26:681–686 - PubMed
-
- Bramhall SR, Allum WH, Jones AG et al (1995) Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 82:111–115. https://doi.org/10.1002/bjs.1800820137 - DOI - PubMed
-
- Crile GJ (1970) The advantages of bypass operations over radical pancreatoduodenectomy in the treatment of pancreatic carcinoma. Surg Gynecol Obstet 130:1049–1053 - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
